Глава 14. Диагностика и лечение больных, относящихся к особым группам населения 677
10. Parsons АО,Butters N, Nathan PE, eds. Neuropsy-chology of alcoholism: implications for diagnosis and treatment. New York: Guilford Press, 1987.
11. Pechter B, Janicak P, Davis JM. Psychopharmaco-therapy for the dually diagnosed. Novel approaches. In: Miller N, ed. The principles and practice of addictions in psychiatry. Philadelphia: WB Saunders, 1997; 521-531.
12. Drake RE, Wallach MA. Substance abuse among the chronic mentally ill. Hosp Cpmm Psychiatry 1989; 40(10) 1041-1045.
13. Smith J, Hucker S. Schizophrenia and substance abuse. Br J Psychiatry 1994:165:13-21.
14. Noordsy DL, Drake RE, Biesanz JC, et al. Family history of alcoholism in schizophrenia. J Nerv Mem Dis 1994; 182:651-655.
15. Sellers EM, Naranjo CA, Peachey JE. Drug therapy: drugs to decrease alcohol consumption. N EnglJMed 1981; 305:1255.
16. Major LF, Lerner P, Ballenge JC, et al. Dopamine beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 1979; 14: 337-344.
17. Kofoed L Outpatient vs. inpatient treatment forthe chronically mentally ill with substance use disorders. J Addict Dis 1993; 12 (3) 123-137.
18. Kofoed L, Kama J, Walsh T, et al. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry 1986; 143: 867-872.
19. Kofoed LL Chemical monitoring ofdisul-firam compliance. A study of alcoholic outpatients. Alcohol Clin Exp Res 1987; 11:481-485.
20. Myers RD, Borg S, Mossberg R. Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol 1986; 3: 383-388.
21. Volpicelli JR, Davis MA, Olgin JE. Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci 1986; 38: 841-847.
22. O'Malley SS, Jaffe A, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49:881-887.
23. Volpicelli JR, Alterman Al, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49= 876-880.
24. Berger P, Watson S, Akil H, et al. The effects of naloxone in chronic schizophrenia. Am J Psychiatry 1981; 138:913-915.
25. Watson SJ, Berger PA, Akil H, et al. Effects of naloxone in schizophrenia: reduction in hallucinations in a subpopulation of subjects. Science 1978; 201: 73-76.
26. Janowsky DS, Judd L, Huey L, et al. Naloxone effects on manic symptoms and growth-hormone levels. Lancet 1978; i: 320.
27. Verhoeven WMA, van Praag HM, de Jong JTVM. Use of naloxone in schizophrenic psychoses and manic syndromes. Neuropsychobiology 1981; 7: 159-168.
28. Emrich HM, Cording C, Piree S, et al. Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmacopsychiatry 1977; 10: 265-270.
29. Ragheb M, Berney S, Ban T. Naltrexone in chronic schizophrenia. Int Pharmacopsychiatry 1980; 15:1-5.
30. Simpson GM, Branchey MH, Lee JH: A trial of naltrexone in chronic schizophrenia. Curr Ther Res 1977; 22 (6): 909-913-
31. Mielke DH, Gaillant DM. An oral opiate antagonist in chronic schizophrenia: a pilot study. Am J Psychiatry 1977; 134:1430-1431-
32. Gitlin M, Rosenblatt M. Possible withdrawal from endogenous opiates in schizophrenics. Am J Psychiatry 1978; 135 (3): 377-378.
33. Dyksen MW, Davis JM. Naloxone in amylobarbi-tone responsive catatonia [Letter]. Br J Psychiatry 1978; 133:476-480.
34. Merikangas KR, Leckman JF, Pursoff BA, et al. Familial transmission of depression and alcoholism. Arch Gen Psychiatry 1985; 42 (4): 367-372.
35. Brown SA, Inaba RK, Gillin JC, et al. Alcoholism and affective disorder: clinical course of depressive symptoms. Am J Psychiatry 1995; 152: 45-52.
36. Brady KT, Killeen T, Jarell P. Depression in alcoholic schizophrenic patients. Am J Psychiatry 1993; 150:1255-1256.
37. Ciraulo DA, Jaffe JH. Tricyclic antidepressants in the treatment of depression associated with alcoholism. J Clin Psychopharmacol 1981; 1: 146-150.
38. Nunes EV, McGrath PJ, Quitkin FM, et al. Imi-pramine treatment of alcoholism with comorbid depression. Am J Psychiatry 1993; 150 (6): 963-965.
39. Gorelick DA. Serotonin uptake blockers and the treatment of alcoholism. Recent Dev Alcohol 1989; 7: 267-281.
678 Принципы и практика психофармакотерапии
40. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992; 16 (2): 261-265.
41. Thomas R. Fluvoxamine and alcoholism. Int Clin Psychopharmacol 1991; 6 (3): 84-92.
42. Amit Z, Brown Z, Sutherland Z, et al. Reduction in alcohol intake in humans as a function of treatment with zimelidine: implications for treatment. In: Naranjo CA, Sellers EM, eds. Research advances in new sychopharmacological treatments for alcoholism. Amsterdam: Excerpta Me-dica, 1985; 189-198.
43. Naranjo CA, Sellers EM, Jullivan JT, et al. The se-rotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987; 41; 266-274.
44. Naranjo CA, Sellers EM, Roach CA, et al. Zimeli-dine-induced variations in alcohol intake by non-depressed heavy drinkers. Clin Pharmacol Ther 1984; 35: 374-381.
45. Naranjo C, Kadlic K, Sanhueza P, Woodley-Rimus D, Kennedy R, Sellers E. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990; 47:490-498.
46. Dorus W, Ostrow DG, Anton R, et aL Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989; 262:1646-1652.
47. Fawcett J, Clark DC, Gibbons RD, et al. Evaluation of lithium therapy for alcoholism. J Clin Psychiatry 1984; 45:494-499.
48. Nagel K, Adler LE, Bell L, et al. Lithium carbonate and mood disorder in recently detoxified alcoholics: a double-blind, placebo-controlled pilot study. Alcohol Clin Exp Res 1991; 15 (6): 978-981.
49. Halikas J, Kuhn K, Carlsan G. The effect of car-bamazepine on cocaine use. Am J Addict 1992; 1 (1): 30-39.
50. Kosten TR, Gawin FH, Kosten ТА, et al. Six-month follow-up of short-term pharmacotherapy for cocaine dependence. Am J Addict 1992; 1 (1): 40-49.
51. Bowen RC, Cipywnyk D, D'Arcy C, et al. Alcoholism, anxiety disorders, and agoraphobia. Alcohol Clin Exp Res 1984; 8:48-50.
52. Smail P, Stockwell T, Canter S, et al. Alcohol dependence and phobic anxiety states I. A prevalence study. Br J Psychiatry 1984; 144: 53-57.
53- Reich J, Chaudhry D. Personality of panic disorder alcohol abusers. J Nerv Ment Dis 1987; 175: 224-228.
54. Cloninger CR, Martin RL, Clayton P, Couze S. Follow-up and family study of anxiety neurosis. In: Klein DF, Rabkin J, eds. Anxiety: new research and changing concepts. New York: Raven Press, 1981.
55. Crowe RR, Crowe RC, Pauls DL, et al. A family study of anxiety neurosis: morbidity risk in families of patients with and without mitral valve prolapse. Arch Gen Psychiatry 1980; 37: 77-79.
56. Starcevic V, Uhlenhuth EH, Kellner R, et al. Co-morbidity in panic disorder: II. Chronology of appearance and pathogenic comorbidity. Psychiatry Res 1993; 46: 285-293.
57. George DT, Nutt DJ, Dwyer BA, et al. Alcoholism and panic disorder: is the comorbidity more than coincidence? Acta Psychiatr Scand 1990; 81:97-107.
58. Ayd FJ Jr, Janicak PG, Davis JM, Preskorn SH. Advances in the pharmacotherapy of anxiety and sleep disorders. In: Janicak PG, ed. Principles and practice of psychopharmacotherapy. Update Vol. I, No. 4.Baltimore: Williams &Wilkins, 1996.
59. Kranzler HR, Burleson JA, Del Boca FK, et al. Bus-pirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994; 51: 720-731.
Психические осложнения при поражении вирусом иммунодефицита человека (ВИЧ) являются одной из наиболее сложных проблем в
практике врача. Подобные больные страдают не только в связи с психотравмирующими социальными и личностными обстоятельствами